[Coronary restenosis]

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Coronary restenosis is a significant complication following arterial interventions, occurring due to the arterial wall's response to mechanical injury.
• It affects approximately 30% of bare-metal stent procedures and 10% of drug-eluting stent procedures.
• The process involves inflammation, cellular proliferation, and extracellular matrix remodeling.

Purpose of the Study:

• To review the mechanisms, risk factors, and therapeutic strategies for coronary restenosis.
• To evaluate the efficacy of different stent types and drug-coated balloons in preventing restenosis.
• To provide guidance on optimal stent selection for interventional cardiology.

Main Methods:

• Literature review and analysis of randomized trials focusing on coronary restenosis.
• Comparison of clinical and angiographic outcomes for bare-metal stents, early-generation drug-eluting stents, latest-generation drug-eluting stents, and drug-coated balloons.
• Examination of the pathophysiology and risk factors associated with restenosis.

Main Results:

• Drug-eluting stents (DES) and drug-coated balloons (DCB) significantly reduce restenosis rates compared to bare-metal stents (BM).
• Latest-generation DES and DCB demonstrate superior clinical and angiographic results for in-stent restenosis.
• Certain medications used in DES, such as rapamycin and paclitaxel, inhibit cell division and influence restenosis outcomes.

Conclusions:

• Latest-generation DES and DCB are recommended for managing coronary restenosis, while BM and first-generation DES should be avoided.
• The mechanism of restenosis with DES can be heterogeneous, involving inflammatory components like T-lymphocytes.
• Further randomized studies are necessary to fully elucidate the role of DES in neoatherosclerosis and optimize treatment strategies.